The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.
Patient-Focused Medicines Development: Where It has Led Us to Today, What Challenges Remain, and What Do We Still Need to Do to Achieve Success?
Lode Dewulf, MD, FFPM
Chief Patient Officer
Using a multi-disciplinary approach, we will take a dynamic look at the experience of those involved in patient engagement, across stakeholder groups representing different regions, to understand
how we have collectively moved the needle. As organizations have embarked upon efforts and implemented initiatives, we will provide a bird’s eye view of the impact of patient engagement across various stakeholders.
Learning Objective : Describe how patient engagement has evolved across stakeholder groups in the past few years
Discuss the impact of collective approaches on patient engagement in medicines development lifecycle
Apply key learnings from collective approaches in their own efforts
Describe recent achievements in patient engagement and identify remaining challenges
Pfizer Inc, United States
Sarah Krug, MS, MSc
Chief Executive Officer
CANCER101, United States
Clinical Trials Transformation Initiative (CTTI), United States
Parkinson's Disease Foundation Initiative, United States